ArticleClinical and experimental immunology1992
Ivermectin-facilitated immunity in onchocerciasis. Reversal of lymphocytopenia, cellular anergy and deficient cytokine production after single treatment.
Article in Clinical and experimental immunology, 1992. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 76 citations in OpenAlex.
- The human immunome in the post-schistosomiasis mass drug administration era.PLoS neglected tropical diseases · 2026Review
- Epilepsy and nodding syndrome in association with an Onchocerca volvulus infection drive distinct immune profile patterns.PLoS neglected tropical diseases · 2023Article
- Onchocerca volvulus-specific antibody and cellular responses in onchocerciasis patients treated annually with ivermectin for 30 years and exposed to parasite transmission in central Togo.PLoS neglected tropical diseases · 2022Article
- Post-Infectious Autoimmunity in the Central (CNS) and Peripheral (PNS) Nervous Systems: An African Perspective.Frontiers in immunology · 2022Review
- Onchocerciasis Fingerprints in the Geriatric Population: Does Host Immunity Play a Role?Tropical medicine and infectious disease · 2021Review
- Inflammatory and regulatory CCL and CXCL chemokine and cytokine cellular responses in patients with patent Mansonella perstans filariasis.Clinical and experimental immunology · 2019Article
- Helminth-Tuberculosis Co-infection: An Immunologic Perspective.Trends in immunology · 2016Review
- Impact of filarial infections on coincident intracellular pathogens: Mycobacterium tuberculosis and Plasmodium falciparum.Current opinion in HIV and AIDS · 2012Review
- Density-dependent mortality of the human host in onchocerciasis: relationships between microfilarial load and excess mortality.PLoS neglected tropical diseases · 2012Article
- Granulocytes in helminth infection -- who is calling the shots?Current medicinal chemistry · 2012Review
- Applied field research for comprehensive helminth infection control.Wiener klinische Wochenschrift · 2010Article
- Effect of chemotherapeutic treatment on cytokine (IFN-gamma, IL-2, IL-4, IL-5, IL-10) gene transcription in response to specific antigens in Brugia malayi-infected Mastomys coucha.Parasitology research · 2008Article
- CD4(+), CD8(+), immunoglobulin status and ocular lesions among some onchocerciasis-infected rural Nigerians.Parasitology research · 2007Article
- Onchocerca volvulus-specific antibody and cytokine responses in onchocerciasis patients after 16 years of repeated ivermectin therapy.Clinical and experimental immunology · 2007Article
- Differential cytokine and antibody responses to adult and larval stages of Onchocerca volvulus consistent with the development of concomitant immunity.Infection and immunity · 2002Article
- A stress-responsive glyoxalase I from the parasitic nematode Onchocerca volvulus.The Biochemical journal · 2001Article
- Onchocerciasis modulates the immune response to mycobacterial antigens.Clinical and experimental immunology · 1999Article
- Population biology of human onchocerciasis.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 1999Article
- Decreased CD4 and increased CD8 counts with T cell activation is associated with chronic helminth infection.Clinical and experimental immunology · 1998Article
- Protective responses against skin-dwelling microfilariae of Onchocerca lienalis in severe combined immunodeficient mice.Infection and immunity · 1997Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A longitudinal investigation has been conducted into the cell-mediated immune responses of onchocerciasis patients after a single-dose treatment with ivermectin. Untreated patients tested for delayed cutaneous hypersensitivity (DCH) to seven recall antigens showed lower responses than infection-free control individuals (P less than 0.01), but 6 and 14 months after treatment DCH reactions increased to similar levels to those seen in the controls. The in vitro cellular reactivity to Onchocerca volvulus-derived antigen (OvAg) was reduced in untreated patients as compared with controls, and the lymphocyte blastogenic responses to OvAg and streptolysin-O clearly improved up to 14 months after treatment. Peripheral blood mononuclear cells (PBMC) from untreated patients produced IL-1 beta, tumour necrosis factor-alpha (TNF-alpha) and IL-6 in response to mitogenic stimulation with phytohaemagglutinin (PHA), only low levels of IL-1 beta, IL-2 and TNF-alpha in response to OvAg, but higher amounts of IL-4 and interferon-gamma (IFN-gamma) in response to OvAg than control individuals. After ivermectin treatment, the OvAg-induced production of IL-1 beta and TNF-alpha increased significantly 1 and 14 months after treatment. The PHA-induced production of IL-2 and IL-4 increased 1 month after treatment and remained significantly elevated until 14 months after treatment, whereas the OvAg-specific secretion of IL-2, IL-4 and IFN-gamma did not change after ivermectin treatment. Flow cytometric analysis of lymphocyte-subsets in the peripheral blood of untreated patients revealed a relative and absolute (P less than 0.01) diminution of CD4+ cells and a significantly smaller CD4+/CD8+ cell ratio as compared with controls. By 4 weeks after treatment and thereafter, CD4+ T cells increased relatively and absolutely (P less than 0.01); likewise there was an absolute increase in T-helper-inducer cells (CD4+CD45RO+) and a temporarily improved CD4+/CD8+ cell ratio (P = 0.001). The expression of the low-affinity receptor for IgE (CD23) on total lymphocytes decreased from 14% to 7% by 14 months after treatment. The CD8+ cells and CD3+TCR gamma delta + cells were higher in patients than in controls and both remained elevated until 14 months after treatment. These results suggest a distinctly improved cellular immunity in human onchocerciasis that was facilitated by ivermectin therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.